The Accidental Discovery That a Tanning Peptide Enhances Sexual Function in Both Sexes

What the researchers found

Melanotan II, a synthetic melanocortin analog originally studied for skin tanning, was found to enhance erectile function in men and increase sexual desire and genital arousal in women. The peptide's mechanism of action is fundamentally different from PDE5 inhibitors like Viagra — it works centrally through melanocortin receptors in the brain rather than peripherally on blood vessels, producing what the author characterizes as a more natural sexual response with minimal side effects.

The sexual effects were discovered accidentally during human skin pigmentation studies, representing a classic example of serendipity in drug discovery.

Why it matters

This accidental discovery launched an entirely new approach to treating sexual dysfunction. Before Melanotan II, sexual enhancement drugs worked on blood flow (Viagra, Cialis). The finding that a peptide could act on the brain to enhance desire and arousal — not just the physical mechanics of sex — opened a new therapeutic frontier. It directly led to the development of bremelanotide (Vyleesi), which became the first FDA-approved treatment for hypoactive sexual desire disorder in premenopausal women in 2019.

How the study worked

This is a brief discovery narrative and commentary by Mac Hadley, the researcher who led the original Melanotan II studies. It summarizes observations from human studies where MTII was being tested for skin pigmentation effects and sexual function enhancement was noted as an unexpected finding.

What this study cannot tell us

This is a brief commentary/narrative, not a systematic study. No specific data, sample sizes, or statistical analyses are presented. The description of "minimal or no undesirable side effects" underplays later-documented side effects of melanocortin agonists, including nausea and blood pressure changes. The piece is written by the discoverer himself, which may introduce bias in the framing of the findings.

How to read the evidence

This is a brief narrative commentary by the original discoverer, not a primary research study. It references but does not present detailed clinical data. The observations described here were later confirmed in formal clinical trials that led to FDA approval of bremelanotide.

When this study was published

Published in 2005, this commentary captures the early history of melanocortin-based sexual function research. The field has matured significantly since then, with bremelanotide (Vyleesi) gaining FDA approval in 2019.

The bigger picture

The Melanotan II story illustrates how one peptide can have multiple, seemingly unrelated effects because its target receptors (melanocortin receptors MC1R through MC5R) are distributed throughout the body. MC1R mediates pigmentation, while MC4R in the brain mediates sexual function. This discovery helped researchers understand the broader melanocortin system and led to drugs targeting specific receptor subtypes — bremelanotide for sexual dysfunction and setmelanotide for genetic obesity.

Questions still open

• Why does a tanning peptide also affect sexual function — what is the evolutionary connection between melanocortin signaling in skin and the brain?
• Could more selective melanocortin receptor agonists achieve sexual function benefits without the tanning and nausea side effects?

Common questions

Read the original research

Discovery that a melanocortin regulates sexual functions in male and female humans.

Peptides, 26(10), 1687-9

Citation

Hadley, Mac E. (2005). Discovery that a melanocortin regulates sexual functions in male and female humans.. Peptides, 26(10), 1687-9.